GlassScriptPhysician profile
Jennifer Yanke
NPI 1467132381
$641.56
in general payments reported to CMS, 2019-2025
13 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $152 · 2024: $251 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159.34 | 2024-2025 | |
| Inspire Medical Systems, INC. | $130.51 | 2023-2025 | Inspire |
| Lilly USA, LLC | $66.26 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $49.17 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $48.99 | 2024-2025 | Breztri |
| Dexcom, INC. | $47.18 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $26.92 | 2025 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $20.58 | 2023 | Camzyos |
| Resmed Corp | $20.04 | 2024 | |
| Xeris Pharmaceuticals, INC. | $19.63 | 2024 | Gvoke Hypopen |
| Pfizer INC. | $19.51 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.35 | 2024 | Jardiance |
| Astellas Pharma US INC | $16.08 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Yanke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.